iShares US Pharmaceuticals ETF
149 hedge funds and large institutions have $345M invested in iShares US Pharmaceuticals ETF in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 43 reducing their positions, and 22 closing their positions.
4% less capital invested
Capital invested by funds: $359M → $345M (-$14.6M)
3.38% less ownership
Funds ownership: 59.25% → 55.86% (-3.4%)
4% less funds holding
Funds holding: 155 → 149 (-6)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
21% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.02M |
| 2 |
LPL Financial
San Diego,
California
|
+$2.69M |
| 3 |
ClearBridge Investments
New York
|
+$1.87M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1,000K |
| 5 |
GS
GTS Securities
New York
|
+$501K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$12.2M |
| 2 |
Morgan Stanley
New York
|
-$11.7M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$5.82M |
| 4 |
Two Sigma Investments
New York
|
-$4.43M |
| 5 |
PCA
Pallas Capital Advisors
Braintree,
Massachusetts
|
-$3.83M |
IHE Hedge Fund Activity: Q1 2025 in Review
149 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2025, worth a combined $345M — down 4.1% from $359M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of IHE and 19 opened new positions — a net loss of 3 holders — while 43 trimmed existing stakes and 34 added.
The largest buyer was Susquehanna International Group, adding an estimated $3.02M. The largest seller was JP Morgan Chase, cutting an estimated $12.2M.
- 149 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2025, down from 155 in Q4 2024.
- Funds reported $345M of iShares US Pharmaceuticals ETF stock for Q1 2025, down 4.1% quarter-over-quarter.
- 19 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2025 and 22 closed out, a net change of -3 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2025 was Susquehanna International Group, an estimated $3.02M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2025 was JP Morgan Chase, an estimated $12.2M sold.
Based on aggregated 13F filings for Q1 2025.